mounjaro es tirzepatide vs. Insulin: Which Is More Effective for Type 2 Diabetes? Mounjaro (tirzepatide) + GLP-1 support

Malic enzyme tracers reveal hypoxia-induced switch in adipocyte NADPH pathway usage

Causes of obesity: a review

21 In the SELECT and FLOW trials, semaglutide reduced heart failure events in people with obesity or overweight and established cardiovascular disease who did not have diabetes and in people with CKD and type 2 diabetes, respectively

Complete semaglutide dosage chart The standard semaglutide escalation schedule was established through the STEP clinical trial program for obesity (using the 2.4 mg target dose marketed as Wegovy) and through earlier trials for type 2 diabetes management (using the 2.0 mg maximum dose marketed as Ozempic)

Tirzepatide's transformative impact begins with its dual-action as a GLP-1 and GIP receptor agonist, enabling it to regulate appetite and blood sugar control simultaneously

Our wellness coaches will guide you in finding enjoyable activities and gradually increasing intensity for sustained weight loss